On January 31, 2025, the European Union reached a major milestone in the modernization of clinical research oversight. The complete migration of trials falling under the Clinical Trial Regulation (CTR) to the Clinical Trials Information System (CTIS) is now finalized. This marks the end of the three-year CTIS transition from the old directive system, establishing a unified and transparent regulatory framework across the European Economic Area (EEA).
All new and ongoing EU clinical trials involving investigational medicinal products—whether alone or in combination with medical devices—must now be managed within the CTIS single gateway. The focus for a Contract Research Organization (CRO) and its sponsors has shifted from whether the system is ready to how they can leverage CTIS modernization to achieve faster clinical trial approval.
CTIS is the mandatory entry point for every clinical trial application, substantial modification, and safety tracking obligation in the EU. This centralized approach ensures harmonized regulatory decisions within reliable and predictable timelines. Transition data from early 2025 confirms high system stability and sustained submission volumes, providing a robust foundation for the next chapter of usability optimization.
The European Medicines Agency (EMA) has successfully reduced submission barriers through continuous CTIS enhancements 2025. Key improvements validated by Member States and sponsor representatives include:
| Workflow area | Stability enhancements delivered |
| Clinical Trial Application (CTA) Submissions | Faster performance and immediate saving of site data have eliminated common errors in application cancellations. |
| Substantial Modification Workflow | The system now maintains a 100% success rate in creating modifications for very large studies, with no missing speech classification (MSC) errors. |
| Notifications & RFIs | Resolved issues with end-of-trial notices and validation Requests for Information (RFIs) ensure smoother communication between sponsors and regulators. |
| Status accuracy | The system now provides correct status displays for withdrawn trials and tacit authorizations, ensuring real-time regulatory clarity. |
| System responsiveness | Significant reductions in timeouts have improved overall workflow continuity. |
The current phase of the CTIS modernization roadmap focuses on reducing the administrative burden on CRO services. Notable functional enhancements include:
| Feature | Benefit |
| Sponsor Management (SM): | A new feature enabling easy transfer of trial ownership between companies. |
| WHO IPD & API Integration | This ensures structured compliance with global trial data standards for immunization-preventable diseases. |
| Optimized Transparency Rules | Redesigned rules offer better protection of commercially confidential information (CCI) while ensuring a balance with public interest. |
| Transitional trial designation flexibility | Sponsors now have increased flexibility for changes via non-substantial modifications (NSMs) and later-stage transitional trial marking. |
| Better notifications + warnings | Clearer alerts and prevention of conflicting draft applications. |
A significant leap in global alignment occurred in April 2025 when CTIS was designated as a WHO Primary Registry. This status ensures that EU clinical trials are fully discoverable in the WHO’s International Clinical Trials Registry Platform (ICTRP). This designation promotes trust in European research and meets the standards required for publication in leading medical journals.
Launched in March 2025, the ACT EU Trial Map is now fully integrated into the CTIS Public Portal. This tool allows patients and healthcare providers to find ongoing trials by medical condition and geographic area. Users can perform lay-language searches, and the map displays site contact information to directly boost recruitment and equitable access.
With stability achieved, the EMA has activated a modernization program designed to simplify business rules and clinical operations. Accenture B.V. now leads the maintenance phase, ensuring continuity and innovation capacity. Future priorities for 2026 include:
CTIS Secure Workspaces: Implementation of workspaces designed to enhance the protection of commercial confidentiality and personal data.
Safety Module Prototype: A new safety module for Annual Safety Reports (ASRs) is expected to go live in early 2026.
Increased Automation: Transitioning to intention-based frameworks to provide more responsive interfaces and clearer role-based access.
Navigating the Clinical Trial Regulation (CTR) requires deep expertise in clinical operations and regulatory support. As a leading European CRO, Palleos provides comprehensive Contract Research Organization (CRO) services to manage your trial’s full regulatory lifecycle.
Our Palleos regulatory services include:
Clinical trial application (CTA) preparation, submission, and EudraCT migration support.
Managing the substantial modification workflow and ongoing regulatory interactions.
Clinical operations support across all EU Member States.
Providing compliance guidance to ensure CRO regulatory compliance Europe remains uncompromised.
The end of the CTIS transition marks a new era of digital-first clinical research. With a stable system now in place, sponsors can look forward to a more accessible and efficient research environment across Europe.
Learn more: https://palleos.com
